Logo

APRE

Aprea Therapeutics, Inc.

APRE

Aprea Therapeutics, Inc. • NASDAQ
$1.26 ▲ 1.20% (+0.01)
Market Cap $7.72 M
52w High $5.00
52w Low $1.08
Dividend Yield 0%
P/E -0.6
Volume 18.44K
Outstanding Shares 6.10M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.848K ▼ $3.114M ▲ $-2.972M ▲ -160.845K% ▼ $-0.47 ▲ $-2.967M ▲
Q2-2025 $118.111K ▼ $1.594M ▼ $-3.239M ▲ -2.742K% ▼ $-0.53 ▲ $-3.382M ▲
Q1-2025 $162.463K ▼ $1.765M ▲ $-3.933M ▼ -2.421K% ▼ $-0.66 ▼ $-4.08M ▼
Q4-2024 $205.817K ▼ $1.073M ▼ $-2.895M ▲ -1.406K% ▼ $-0.49 ▲ $-3.221M ▲
Q3-2024 $354.621K $1.605M $-3.784M -1.067K% $-0.64 $-4.092M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $13.718M ▼ $14.321M ▼ $2.681M ▼ $11.64M ▼
Q2-2025 $16.532M ▼ $17.31M ▼ $3.895M ▼ $13.415M ▼
Q1-2025 $19.276M ▼ $20.222M ▼ $4.672M ▲ $15.55M ▼
Q4-2024 $22.85M ▼ $23.979M ▼ $4.672M ▼ $19.307M ▼
Q3-2024 $26.25M $26.894M $4.947M $21.947M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.972M ▲ $-3.263M ▼ $0 $370.686K ▼ $-2.814M ▼ $-3.263M ▼
Q2-2025 $-3.239M ▲ $-3.131M ▲ $0 $384.879K ▲ $-2.743M ▲ $-3.131M ▲
Q1-2025 $-3.933M ▼ $-3.631M ▼ $0 $55.849K ▼ $-3.574M ▼ $-3.631M ▼
Q4-2024 $-2.895M ▲ $-3.511M ▼ $0 $134.405K ▲ $-3.401M ▼ $-3.511M ▼
Q3-2024 $-3.784M $-2.468M $0 $-1.155K $-2.445M $-2.468M

Five-Year Company Overview

Income Statement

Income Statement Aprea is still a pure R&D biotech story: it has no product revenue yet, so its income statement is entirely driven by research and overhead costs. Losses have been consistent over the years, which is normal for an early‑stage drug developer. The one standout year of very large reported loss looks more like an accounting or restructuring impact than a change in the underlying business. More recently, losses appear to have narrowed somewhat, suggesting tighter cost control, but the business is still firmly in the “spend to develop” phase rather than earning phase.

Balance Sheet

Balance Sheet The balance sheet is simple and relatively clean. Assets are small but largely made up of cash, with no financial debt reported. Equity roughly matches total assets, meaning the company has been funded mainly through issuing shares rather than borrowing. Over time, the asset and equity base has gradually shrunk as cash is spent on R&D, which is expected for a company without revenue. The key question is not leverage risk—there’s essentially no debt—but how long existing cash can support clinical programs before new funding is needed.

Cash Flow

Cash Flow Cash flow reflects a classic clinical‑stage biotech profile: steady cash outflows from operations and no meaningful capital spending. The company’s cash burn has been relatively stable, with free cash flow negative but not erratic. This indicates disciplined but ongoing funding needs, rather than sudden spikes. Based on the company’s own guidance, the current cash position is expected to last for a limited number of years, so additional capital or partnerships will likely be required to continue trials beyond that horizon.

Competitive Edge

Competitive Edge Aprea operates in a high‑value but crowded corner of oncology, targeting DNA damage response pathways. Its edge is a focus on next‑generation chemistry and biomarker‑selected patients, which could allow it to carve out specific niches rather than compete broadly with large pharma on every front. However, it is small relative to major players already developing similar WEE1 and ATR inhibitors, so timelines, trial design, and differentiation on safety or efficacy will be critical. The competitive risk is that larger companies may set the clinical standard before Aprea’s programs mature, but the company can still compete if its drugs show clearly better tolerability or work in especially well‑defined patient groups.

Innovation and R&D

Innovation and R&D Innovation is where Aprea is strongest. It is advancing two key programs: a next‑generation WEE1 inhibitor (APR‑1051) and a first‑in‑class macrocyclic ATR inhibitor (ATRN‑119). Both are designed to hit cancer cells’ DNA repair vulnerabilities more selectively, aiming for fewer side effects than earlier drugs in these classes. The pipeline is still early, but initial safety signals are encouraging and the company is using a precision oncology approach—matching drugs to specific genetic alterations—to boost the odds of clear trial results. Aprea has also been building an intellectual property estate that could protect these assets well into the next decade, which is important if the drugs reach approval.

Summary

Overall, Aprea is a classic early‑stage oncology biotech: no revenue, ongoing losses, a lean but debt‑free balance sheet, and steady cash burn focused on R&D. Its value hinges almost entirely on the success of its two DDR‑targeting cancer drugs. Strengths include a focused scientific strategy, differentiated chemistry, a biomarker‑driven development plan, and a growing patent portfolio. Main risks are clinical (whether the drugs work well enough and safely enough), financial (the need for future funding as cash is spent), and competitive (larger players advancing similar mechanisms). Upcoming clinical data readouts and any partnering activity will be the key milestones to watch to gauge how the story is evolving.

NEWS

November 12, 2025 · 8:30 AM UTC

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Read more

October 24, 2025 · 8:30 AM UTC

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Read more

October 15, 2025 · 8:00 AM UTC

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Read more

October 14, 2025 · 8:00 AM UTC

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Read more